Transcriptome and methylome of human CD4? CLA? T cells in healthy controls and atopic dermatitis patients treated with dupilumab or upadacitinib
Skin-homing CD4?CLA? T cells are involved in chronic AD inflammation and may carry long-lived disease-modifying effects through stable DNA methylation programs. By profiling the DNA methylome of healthy individuals and AD patients before and after one year of dupilumab or upadacitinib. This study tests whether these therapies facilitate epigenetic reprogramming. Using flow cytometry, CD4+CLA+ T cells were isolated from AD patients (n=12) at baseline and after 52 weeks of dupilumab (n=6) or upadacitinib (n=6) treatment. Non-atopic healthy controls (HC) (n=6) were included for comparison.
Skin-homing CD4?CLA? T cells are involved in chronic AD inflammation and may carry long-lived disease-modifying effects through stable DNA methylation programs. By profiling the DNA methylome of healthy individuals and AD patients before and after one year of dupilumab or upadacitinib. This study tests whether these therapies facilitate epigenetic reprogramming. Using flow cytometry, CD4+CLA+ T cells were isolated from AD patients (n=12) at baseline and after 52 weeks of dupilumab (n=6) or upadacitinib (n=6) treatment. Non-atopic healthy controls (HC) (n=6) were included for comparison.
University Medical Center Utrecht